HanAll\'s Partner HBM Announces IND Approval for Phase 2 of Batoclimab in CIDP in China
2021.09.02

 

HanAll Biopharma (KRX: 009420.KS) today announced that its partner for HL161(batoclimab) & HL036(tanfanercept)​ for the Chinese market, Harbour BioMed, has received IND approval for Phase 2 of batoclimab in patients with chronic inflammatory demyelinating polyneuropathy(CIDP) in China. The company is now pursuing 5 autoimmune diseases including myasthenia gravis(MG), grave’s ophthalmopathy(GO), adult immune thrombocytopenia(ITP), neuromyelitis optica spectrum disorder(NMOSD), and​ chronic inflammatory demyelinating polyneuropathy(CIDP)​ in the region.​

 

For more information, please refer to the link below.

- HBM press release link: https://www.harbourbiomed.com/news/164.html​